Bank of America
BCTXW

Bank of America’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

Bank of America’s Portfolio BCTXW Stock Details BCTXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-472
Closed -$972 – 7806
2022
Q4 		$972 Buy
+472
New +$1.1K ﹤0.01% 7350

Other funds holding BCTXW

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $706M AUM 48.92% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Bank of America's BCTXW Position: Q1 2023 in Review

Bank of America sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q1 2023, closing a stake of 472 shares — an estimated $972 sold.

Bank of America first reported a position in BCTXW in Q4 2022 and held it in 1 quarter. The position peaked at $972 in Q4 2022. 4 funds tracked by Wall St. Rank hold BCTXW as of Q1 2023.

  • Bank of America reported no remaining BriaCell Therapeutics Corp Warrant position as of Q1 2023 after selling out during the quarter.
  • Bank of America sold 472 BriaCell Therapeutics Corp Warrant shares in Q1 2023, an estimated $972.
  • Bank of America first reported a position in BriaCell Therapeutics Corp Warrant in Q4 2022 and held it in 1 quarter.
  • Bank of America's BriaCell Therapeutics Corp Warrant position peaked at $972 in Q4 2022.
  • 4 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q1 2023.

Based on Bank of America's 13F filing for Q1 2023, filed 12 May 2023.